David P Humphreys
Overview
Explore the profile of David P Humphreys including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
630
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Rowley T, Peters S, Aylott M, Griffin R, Davies N, Healy L, et al.
Commun Biol
. 2018 Oct;
1:146.
PMID: 30272022
Autoantibody-mediated diseases are currently treated with intravenous immunoglobulin, which is thought to act in part via blockade of Fc gamma receptors, thereby inhibiting autoantibody effector functions and subsequent pathology. We...
12.
Stoyle C, Stephens P, Humphreys D, Heywood S, Cain K, Bulleid N
Biochem J
. 2017 Aug;
474(18):3179-3188.
PMID: 28784690
Rodent monoclonal antibodies with specificity towards important biological targets are developed for therapeutic use by a process of humanisation. This process involves the creation of molecules, which retain the specificity...
13.
Monaghan T, Negm O, MacKenzie B, Hamed M, Shone C, Humphreys D, et al.
Clin Exp Gastroenterol
. 2017 Aug;
10:169-175.
PMID: 28765714
Objectives: Despite multiple risk factors and a high rate of colonization for , the occurrence of infection in patients with cystic fibrosis is rare. The aim of this study was...
14.
Ellis M, Patel P, Edon M, Ramage W, Dickinson R, Humphreys D
Biotechnol Prog
. 2016 Oct;
33(1):212-220.
PMID: 27790865
Humanized Fab' fragments may be produced in the periplasm of Escherichia coli but can be subject to degradation by host cell proteases. In order to increase Fab' yield and reduce...
15.
Dave E, Adams R, Zaccheo O, Carrington B, Compson J, Dugdale S, et al.
MAbs
. 2016 Aug;
8(7):1319-1335.
PMID: 27532598
An antibody format, termed Fab-dsFv, has been designed for clinical indications that require monovalent target binding in the absence of direct Fc receptor (FcR) binding while retaining substantial serum presence....
16.
Adams R, Griffin L, Compson J, Jairaj M, Baker T, Ceska T, et al.
MAbs
. 2016 Jun;
8(7):1336-1346.
PMID: 27315033
We generated an anti-albumin antibody, CA645, to link its Fv domain to an antigen-binding fragment (Fab), thereby extending the serum half-life of the Fab. CA645 was demonstrated to bind human,...
17.
Pacholarz K, Peters S, Garlish R, Henry A, Taylor R, Humphreys D, et al.
Chembiochem
. 2015 Nov;
17(1):46-51.
PMID: 26534882
The aggregation of protein-based therapeutics such as monoclonal antibodies (mAbs) can affect the efficacy of the treatment and can even induce effects that are adverse to the patient. Protein engineering...
18.
Humphreys D, Wilcox M
Clin Vaccine Immunol
. 2014 May;
21(7):913-23.
PMID: 24789799
Antibodies for the treatment of Clostridium difficile infection (CDI) have been demonstrated to be effective in the research and clinical environments. Early uncertainties about molecular and treatment modalities now appear...
19.
Davies N, Compson J, MacKenzie B, ODowd V, Oxbrow A, Heads J, et al.
Clin Vaccine Immunol
. 2013 Jan;
20(3):377-90.
PMID: 23324518
Clostridium difficile infections are a major cause of antibiotic-associated diarrhea in hospital and care facility patients. In spite of the availability of effective antibiotic treatments, C. difficile infection (CDI) is...
20.
Heads J, Adams R, DHooghe L, Page M, Humphreys D, Popplewell A, et al.
Protein Sci
. 2012 Jul;
21(9):1315-22.
PMID: 22761163
The stability of therapeutic antibodies is a prime pharmaceutical concern. In this work we examined thermal stability differences between human IgG1 and IgG4 Fab domains containing the same variable regions...